Journal Guide

Drug Resistance Updates is a bimonthly publication that contains thought-provoking reviews on important developments in drug resistance in infectious disease and cancer as well as novel drugs and strategies to overcome drug resistance.It covers both basic research and clinical aspects of drug resistance, and involves disciplines as diverse as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective.*Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research

Endocrine-Related Cancer is the established global journal for basic, translational and clinical research on hormones and cancer. Endocrine-related cancers typically include cancers of the breast, prostate, pituitary, testes, ovary and neuroendocrine system as well as hormone-dependent cancers elsewhere.

The European Journal of Cancer (EJC) is an international multidisciplinary oncology journal, which publishes original research, reviews, and editorial comments on basic and preclinical cancer research, translational oncology, clinical oncology - including medical oncology, paediatric oncology, radiation oncology, and surgical oncology, and cancer epidemiology and prevention.The EJC is the official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).Why publish your work in the EJC?Efficient peer-review: The EJC's Editors and reviewers are committed to maintaining the high standards of the journal. All manuscripts submitted to the EJC will be evaluated by the journal's Editors. Some manuscripts may be rejected outright following this evaluation, allowing the authors to submit their work elsewhere. Those manuscripts which are judged as being eligible for consideration by the Editors will be subject to peer-review. The full peer-review policy for the EJC can be found here.The EJC has an online submission and peer-review system to facilitate the submission and peer-review of submitted manuscripts. Authors are able to upload their manuscript quickly and track the status of their manuscript throughout the review process.Online Publication as an Article-in-Press: All manuscripts that are accepted for publication in the EJC are published online as Articles-in-Press within 4 - 5 weeks of acceptance. Articles-in-Press can be cited using the unique digital object identifier (DOI) which is assigned to all papers. In addition, Articles-in-Press are indexed in PubMed.The EJC's readership: The EJC is published in print and online and is available to more than 17,000 academic and clinical institutions, personal subscribers and members of the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA). In 2011 the journal had more than 83,000 articles downloaded per month from across the world.The EJC has an iPad app, making each issue of the journal available to our readers in this format. Visit http://itunes.apple.com/us/app/ejc-app/id461022524?mt=8 to find out more.eTables of Contents: Our readers can elect to receive free eTables of Contents via email, which are sent out for each issue of the journal.Abstracting and Indexing Coverage: The EJC is included in the leading abstracting and indexing services, including PubMed/MEDLINE, Current Contents/Clinical Medicine, the Science Citation Index, the Journal Citation Reports and Scopus.HINARI: The EJC is part of HINARI (Health InterNetwork Access to Research Initiative) administered by the World Health Organisation. The HINARI Programme enables developing countries to gain access to one of the world's largest collections of biomedical and health literature.Why read the EJC?High quality original research and review articles: The EJC is a multidisciplinary journal, publishing high quality original research and review articles on basic and preclinical research, translational oncology, clinical oncology (medical, paediatric, radiation, surgical), and cancer epidemiology and prevention from across the world.Guidelines: The EJC is privileged to publish selected treatment guidelines from the journal's Society Partners (the EORTC, ECCO, EACR and EUSOMA) and other groups.Special Series: The EJC publishes special series of papers on linked topics of particular relevance and interest to the journal's readers.EJC News and EJC News Focus: Each month, the journal publishes the EJC News, discussing and commenting on current issues in cancer, together with the EJC News Focus, a series of video interviews with key opinion leaders in oncology.

EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal's websites.EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention.Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief.EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European Association for Cancer Research (EACR), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).

The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: Primary, secondary and tertiary care for cancer patients Multidisciplinary and service-user involvement in cancer care Rehabilitation, supportive, palliative and end of life care for cancer patients Policy, service development and healthcare evaluation in cancer care Psychosocial interventions for patients and family members International perspectives on cancer care The journal provides a forum for multiprofessional and service-user dialogue, and the reporting of original research or rigorous reviews within the field of cancer care both in Europe and internationally. The journal welcomes original research, reviews and correspondence from individuals whose first language is not English, but places great weight in its published papers on accuracy, fluency and clarity of expression as befits any journal published for an international and multiprofessional audience.

The European Journal of Cancer Prevention emphasizes the rapid publication of important research into fundamental aspects of cancer prevention, making it essential reading for researchers in a wide variety of fields. The scope is wide ranging, including descriptive and metabolic epidemiology, histopathology, lifestyle issues, environment, genetics, biochemistry, molecular biology, microbiology, clinical medicine, intervention trials and public education, basic laboratory studies and special group studies.Website: www.eurjcancerprev.com.

The European Journal of Oncology Nursing's 2012 Impact Factor is 1.685 (© Thomson Reuters Journal Citation Reports 2013).The European Journal of Oncology Nursing is an international journal which publishes research of direct relevance to patient care, nurse education, management and policy development. EJON is proud to be the official journal of the European Oncology Nursing Society.The journal publishes the following types of papers:• Original research articles• Review articles• Commentaries• Practice Notes• Book and media reviews• A scan of current literatureBenefits to authorsWe also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our support pages: http://support.elsevier.com

European Journal of Surgical Oncology's 2012 Impact Factor is 2.614 (© Thomson Reuters Journal Citation Reports 2013).EJSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery.The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.The Editors welcome submissions on clinical research and all other aspects of surgical oncology which advance the care of patients with cancer, including surgical quality control, epidemiology, preventative aspects of surgical oncology, as well as translational research relevant to surgical oncology practice.

Experimental Cell Research promotes the understanding of cell biology by publishing experimental studies on the general organization and activity of cells. The scope of the journal includes all aspects of cell biology, from the molecular level to the level of cell interaction and differentiation.Experimental Cell Research publishes papers in the area of cell and molecular biology, and papers must provide novel and significant insights into important problems in these areas. Areas of interest include, but are not restricted to:- Apoptosis and programmed cell death- Cancer research- Cell cycle- Cell proliferation and differentiation- Cellular motility and migration- Cell-cell and cell-matrix interaction- Chromatin- Chromosome structure and dynamics- Cytoskeleton- Developmental biology- DNA repair- Epigenetics- Extracellular matrix- Gene regulation- Intracellular trafficking- Mammalian genetic models- Meiosis and mitosis- MicroRNA- Nuclear import-export- RNA processing- Signal transduction- Stem cell biology- Subcellular organizationExperimental Cell Research has partnered with Gastroenterologyhttp://www.gastrojournal.org/ to offer fast track review for certain articles. Articles rejected from Gastroenterology because of their strong biological focus may be directed to ECR for fast track review. Similarly, articles deemed too clinical for ECR and more appropriate for Gastroenterology may be fast tracked through Gastroenterology's review process. Both journals retain editorial independence and reserve the right to request additional changes, re-review, or reject manuscripts.

Experimental Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology with emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.Experimental Hematology & Oncology aims to publish original work, hypothesis, commentaries and timely reviews in the closely related fields of hematology and oncology.With open access, rapid turnaround time from submission to publication and online live comments from readers, Experimental Hematology & Oncology will strive to be the hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the field of hematology and oncology.

Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.

Clinical cancer genetics has now matured to a truly multidisciplinary medical discipline in which clinical and molecular geneticists work with clinical and medical oncologists as well as with psycho-social workers.Due to the multidisciplinary nature of clinical cancer genetics most papers are currently being published in a wide variety of journals on epidemiology, oncology and genetics. Familial Cancer provides a forum bringing these topics together, focusing on the interests and needs of the clinician.The journal concentrates on clinical cancer genetics. Most major areas in the field are included, such as epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counseling and the health economics of familial cancer.